Abstract
This study aimed to indicate whether autologous bone marrow cell infusion (ABMI) via the right omental vein (ROV) could have a regulatory effect on decompensated liver cirrhosis (DLC) patients with type 2 diabetes mellitus (T2DM). For this purpose, 24 DLC patients with T2DM were divided into observation group (n=14) and control group (n=10). Patients in the observation group were given ABMI through the ROV and right omental artery (ROA), and cases in the control group received ABMI through the ROV. At 1, 3, 6, and 12months after ABMI, it was revealed that the prothrombin time, the total bilirubin levels, and the amount of ascites were significantly lower, while the serum albumin levels in the two groups were markedly higher compared with those before ABMI (p<0.01), and there was no significant difference between the two groups at each time point (p>0.05). The fasting blood glucose and glycosylated hemoglobin levels at 6 and 12months after ABMI in the two groups significantly decreased compared with those before ABMI (p<0.05 or p<0.01), while the decreased levels in the observation group were more obvious than those in the control group at each time point (p<0.01). The amount of insulin in the observation group at 3, 6, and 12months after ABMI was significantly less than that before ABMI in the control group (p<0.01). In summary, ABMI showed a significant therapeutic efficacy for DLC patients with T2DM through ROV and ROA.
Highlights
Cirrhosis is as a late stage of scarring of the liver caused by liver diseases and conditions, such as hepatitis B virus (HBV)-induced cirrhosis, alcoholic cirrhosis, schistosomiasisinduced cirrhosis, metabolic cirrhosis, cholestasis cirrhosis, and cirrhosis of unknown etiology, and the most common type is HBV-induced cirrhosis in China (Chang et al, 2017)
Inclusion Criteria Computed tomography (CT) scans showed that the volume of each lobe of the liver was significantly reduced, as well as displaying a cirrhotic liver with an irregular shape and splenomegaly; occurrence of peritoneal effusion; satisfying the diagnostic criteria for decompensated liver cirrhosis (DLC) and type 2 diabetes mellitus (T2DM)
Exclusion Criteria Patients’ age < 18 years old; pregnant and lactating women; malignant tumors in the liver or other organs; patients with spontaneous bacterial peritonitis or gastrointestinal bleeding; patients with acute heart failure, respiratory insufficiency, or other diseases who were intolerant to treatment; patients who underwent hormone therapy; patients with intellectual disabilities or mental disorders who were unable to participate in surgery and follow-up
Summary
Cirrhosis is as a late stage of scarring (fibrosis) of the liver caused by liver diseases and conditions, such as hepatitis B virus (HBV)-induced cirrhosis, alcoholic cirrhosis, schistosomiasisinduced cirrhosis, metabolic cirrhosis, cholestasis cirrhosis, and cirrhosis of unknown etiology, and the most common type is HBV-induced cirrhosis in China (Chang et al, 2017). ABMI for DLC Patients With T2DM quickly to the stage of cirrhosis. Serious complications, including decreased hepatic functional capacity, ascites, gastrointestinal bleeding, and even hepatic encephalopathy may occur. Cirrhosis leads to abnormal glucose metabolism, and the elevated blood glucose level enhances damage to liver function and forms a vicious circle. Clinical treatment for cirrhosis is a highly complicated process (Xu et al, 2019; Michel et al, 2020), seriously influencing the quality of life and health of patients with cirrhosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.